Polycystic Ovarian Syndrome - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Polycystic Ovarian Syndrome - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Polycystic Ovarian Syndrome - Pipeline Review, H2 2016', provides an overview of the Polycystic Ovarian Syndrome pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome
- The report reviews pipeline therapeutics for Polycystic Ovarian Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Polycystic Ovarian Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Polycystic Ovarian Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table Of Content

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Polycystic Ovarian Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Polycystic Ovarian Syndrome - Overview 8
Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis 9
Polycystic Ovarian Syndrome - Therapeutics under Development by Companies 10
Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes 11
Polycystic Ovarian Syndrome - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Polycystic Ovarian Syndrome - Products under Development by Companies 16
Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes 17
Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development 18
Addex Therapeutics Ltd 18
Crinetics Pharmaceuticals, Inc. 19
EffRx Pharmaceuticals S.A. 20
Euroscreen S.A. 21
Merck KGaA 22
Millendo Therapeutics, Inc. 23
Vicore Pharma AB 24
Polycystic Ovarian Syndrome - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
C-21 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
choriogonadotropin alfa - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ESN-364 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
JDSCR-004 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
KDT-501 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
metformin hydrochloride - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
MLE-4901 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Polycystic Ovarian Syndrome - Dormant Projects 47
Polycystic Ovarian Syndrome - Discontinued Products 48
Polycystic Ovarian Syndrome - Product Development Milestones 49
Featured News & Press Releases 49
Aug 16, 2016: Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome 49
Jul 27, 2016: Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome 49
Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials 50
Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients 50
Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364 51
Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting 51
Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome 51
Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364 52
Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations 52
Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List Of Tables

Number of Products under Development for Polycystic Ovarian Syndrome, H2 2016 8
Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Comparative Analysis by Unknown Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Polycystic Ovarian Syndrome - Pipeline by Addex Therapeutics Ltd, H2 2016 18
Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016 19
Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals S.A., H2 2016 20
Polycystic Ovarian Syndrome - Pipeline by Euroscreen S.A., H2 2016 21
Polycystic Ovarian Syndrome - Pipeline by Merck KGaA, H2 2016 22
Polycystic Ovarian Syndrome - Pipeline by Millendo Therapeutics, Inc., H2 2016 23
Polycystic Ovarian Syndrome - Pipeline by Vicore Pharma AB, H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Polycystic Ovarian Syndrome - Dormant Projects, H2 2016 47
Polycystic Ovarian Syndrome - Discontinued Products, H2 2016 48